Details of the Drug

General Information of Drug (ID: DM10D85)

Drug Name

Edetic acid

Synonyms

Ethylenediaminetetraacetic acid; EDTA; 60-00-4; Edathamil; Versene; Titriplex; Havidote; EDTA acid; Sequestrol; Cheelox; Sequestric acid; Warkeelate acid; Gluma cleanser; Sequestrene aa; Komplexon ii; Versene acid; Tetrine acid; Quastal Special; Metaquest A; Trilon bw; Complexon II; Titriplex II; Hamp-ene acid; Cheelox BF acid; Trilon BS; Celon A; Questex 4H; Chelest 3A; Celon ATH; Chemcolox 340; Versenate; Acidum edeticum; Universne acid; Acido edetico; Acide edetique; Vinkeil 100; Dissolvine E; Nullapon B acid; Perma

Indication

Disease Entry	ICD 11	Status	REF
Hypercalcaemia	5B91.0	Approved	[1]
Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

292.24

Logarithm of the Partition Coefficient (xlogp)

-5.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Elimination: 95% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 20 - 60 minutes [4]
Metabolism: The drug is not metabolised []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 66.033 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 91 mg/mL [3]

Chemical Identifiers

Formula: C10H16N2O8
IUPAC Name: 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
Canonical SMILES: C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
InChI: InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)
InChIKey: KCXVZYZYPLLWCC-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 6049
ChEBI ID: CHEBI:42191
CAS Number: 60-00-4
DrugBank ID: DB00974
TTD ID: D00KEP

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Elegans Endoprotease bli-4 (Elegans bli-4)	TT0VH8G	BLI4_CAEEL	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensin-converting enzyme (ACE)	OTDF1964	ACE_HUMAN	Gene/Protein Processing	[6]
Aspartoacylase (ASPA)	OTR2MWS4	ACY2_HUMAN	Gene/Protein Processing	[7]
Calcium/manganese antiporter SLC30A10 (SLC30A10)	OTXM5JW4	ZNT10_HUMAN	Gene/Protein Processing	[8]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Gene/Protein Processing	[9]
Integrin alpha-M (ITGAM)	OTAG6HWU	ITAM_HUMAN	Gene/Protein Processing	[10]
L-selectin (SELL)	OT6RAJZR	LYAM1_HUMAN	Gene/Protein Processing	[10]
Metallothionein-3 (MT3)	OTVCZ7HI	MT3_HUMAN	Post-Translational Modifications	[11]
Neutrophil collagenase (MMP8)	OTZXH19L	MMP8_HUMAN	Gene/Protein Processing	[12]
Thioredoxin reductase 1, cytoplasmic	OTPY3OKU	TRXR1_HUMAN	Gene/Protein Processing	[13]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Experimental hypercalcaemia and whole blood clotting. J Clin Pathol. 1973 Aug;26(8):616-9.
2	Removal of the glycosylphosphatidylinositol anchor from PrP(Sc) by cathepsin D does not reduce prion infectivity. Biochem J. 2006 Apr 15;395(2):443-8.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	(-)-Epigallocatechin-3-gallate inhibits human angiotensin-converting enzyme activity through an autoxidation-dependent mechanism. J Biochem Mol Toxicol. 2017 Sep;31(9). doi: 10.1002/jbt.21932. Epub 2017 May 23.
7	Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease. FEBS Lett. 2006 Oct 30;580(25):5899-904. doi: 10.1016/j.febslet.2006.09.056. Epub 2006 Oct 2.
8	Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012 Mar 9;90(3):467-77.
9	Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
10	Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential. Cardiovasc Res. 1995 Nov;30(5):676-81. doi: 10.1016/0008-6363(95)00069-0.
11	Protective effect of metallothionein-III on DNA damage in response to reactive oxygen species. Biochim Biophys Acta. 2002 Oct 10;1573(1):33-8. doi: 10.1016/s0304-4165(02)00325-2.
12	Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology. 2004 Apr;126(4):1122-33; discussion 949. doi: 10.1053/j.gastro.2003.12.045.
13	Characterization of alternative cytosolic forms and cellular targets of mouse mitochondrial thioredoxin reductase. J Biol Chem. 2006 Aug 11;281(32):22953-63.
14	Mechanistic-based non-animal assessment of eye toxicity: Inflammatory profile of human keratinocytes cells after exposure to eye damage/irritant agents. Chem Biol Interact. 2018 Aug 25;292:1-8. doi: 10.1016/j.cbi.2018.06.031. Epub 2018 Jun 25.